AGN News and Press, Allergan plc From 02/22/20

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

The privately owned BTL Industries officially announced that it had filed a lawsuit against Allergan (NYSE: AGN) , claiming that the company had run a false and deceptive advertising campaign against BTL's non-invasive muscle-toning product. According to details from the lawsuit, Allergan's ...

Privately held BTL Industries has filed a lawsuit in a Delaware court against Allergan ( AGN -0.4% ) over its "deceptive" advertising of its CoolTone body contouring treatment compared to BTL's Emsculpt . Specifically, BTL seeks cash compensation from Allergan, including all profits fro...

Seventeen consumer groups and unions have again voiced their opposition to AbbVie 's (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in a letter to the Federal Trade Commission. The organizations, which represent over 10 million subscribers and members, originally raised concerns in Se...

Each quarter, I spend a day or so, reading Form 13F filings from the hedge funds that specialize in merger arb, documenting, and analyzing which merger stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share it here on Seeking ...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

The stock market has been bullish for years now, and most companies are richly valued as a result. Meanwhile, dividend yields remain low -- right now, the  SPDR S&P 500 ETF (NYSEMKT: SPY) offers just 1.7%. What's an investor seeking returns to do? One attractive option is the pharm...

DUBLIN , Feb. 14, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of t...

At first glance, the picture for AbbVie (NYSE: ABBV) looks bad. The company's top-selling drug that generated over half of the company's total revenue in the past has lost patent exclusivity in Europe and will do so in the U.S. within the next three years. Last year, while the overall market...

DUBLIN , Feb. 14, 2020 /PRNewswire/ -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM   8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL&...